Amir Goldkorn, MD Discusses Baseline CTC Count as a Prognostic Marker of PSA Response and Progression in mCSPC
May 30, 2020
Baseline CTC counts were shown to be strong indicators for subsequent therapy response and 2-year progression-free survival.
Recent Content
Teclistamab Shows Promise for Patients with Relapsed/Refractory Myeloma
May 30, 2020
Teclistamab appeared to be a safe and efficacious treatment for patients with relapsed/refractory multiple myeloma, according to a phase I study presented at the ASCO Virtual Scientific Program.
Karen H. Lu, MD, on Addresses Gap in Genetic Counseling for Women at Risk for Ovarian Cancer
May 30, 2020
The MD Anderson Cancer Center expert spoke about the disconnect in women who are at risk for ovarian cancer to actually receive genetic counseling.
Off-the-Shelf CAR T-Cell Therapy Shows Promise in Relapsed/Refractory B-Cell Lymphomas
May 30, 2020
The allogeneic CAR-T cell therapy ALLO-501, paired with the monoclonal antibody ALLO-647, demonstrated clinical responses and manageable toxicity in patients with pretreated large B-cell and follicular lymphomas in the Phase I ALPHA trial.
Pembrolizumab Shows Superior PFS in Relapsed/Refractory Classical Hodgkin Lymphoma
May 30, 2020
Results of KEYNOTE-204 supports pembrolizumab as new standard of care for patients with classical Hodgkin Lymphoma who have relapsed after autologous stem cell transplant or are ineligible for autologous stem cell transplant.
FDA Approves Ramucirumab Injection in Combination with Erlotinib for NSCLC
May 30, 2020
The FDA approved ramucirumab injection in combination with erlotinib for the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 mutations.
Nivolumab/Ipilimumab Combo Yields Durable Efficacy in Advanced NSCLC
May 30, 2020
Frontline treatment with nivolumab plus ipilimumab induced durable and long-term efficacy, compared with chemotherapy, in patients with advanced non-small cell lung cancer, regardless of PD-L1 expression.
Mirvetuximab Soravtansine Combination Yields Encouraging Response Rates in Ovarian Cancer
May 30, 2020
A study presented at the 2020 ASCO Scientific Program combining mirvetuximab soravtansine with bevacizumab to treat platinum-agnostic ovarian cancer demonstrated an encouraging overall response rate and tolerability profile regardless of platinum status.
Phase III HERO Trial Finds Relugolix to be Superior to Leuprolide in Prostate Cancer
May 30, 2020
The results suggested the potential for this agent to become a new standard for T-suppression in this patient population.
Eric Jonasch, MD, Discusses Use of MK-6482 in VHL Disease–Associated Kidney Cancer
May 30, 2020
The HIF-2a Inhibitor, MK-6482, induced clinical responses among patients with von Hippel-Lindau disease–associated renal cell carcinoma.
